Effects of Dietary Creatine Monohydrate Supplementation and Resistance Training on Late Onset Doxorubicin‐Induced Skeletal Muscle Dysfunction and MyoD Expression
Benjamin A Kugler,Michael J Capps,David S Hydock
DOI: https://doi.org/10.1096/fasebj.31.1_supplement.lb745
2017-04-01
The FASEB Journal
Abstract:The chemotherapy drug doxorubicin (DOX) has been shown to cause skeletal muscle dysfunction and reductions in MyoD gene expression. Creatine monohydrate (Cr) supplementation and resistance training (RT), however, have been shown to increase MyoD expression and improve skeletal muscle function, but their effects on DOX myotoxicity have yet to be explored. The aim of this study was to determine the effects of DOX treatment, RT, Cr, and combined Cr and RT on late‐onset DOX myotoxicity and MyoD expression. Male rats randomly assigned to control diet+sedentary+saline (SS), control diet+sedentary+DOX (SD), control diet+RT+DOX (RD), Cr+sedentary+DOX (CrSD), and Cr+RT+DOX (CrRD) were fed either standard rodent chow or a diet supplemented with 3% Cr for 40 days, and on day 14, animals received daily 1 mg/kg DOX injections for 12 consecutive days (12 mg/kg cumulative) or saline as a placebo. After injections, RD and CrRD were housed in cages where food and water were gradually raised to act as a RT model. Forelimb grip strength was assessed at baseline and throughout the 40‐day treatment period. Following drug treatments and dietary/exercise interventions, the right soleus (SOL) and extensor digitorum longus (EDL) were excised and analyzed for MyoD expression using Western blotting. From baseline to day 40, SS had an increase in grip strength (+20%, P 0.05); however, an increase in grip strength over the 40‐day period was observed in CrRD (+25%, P<0.05). In the SOL, no between group differences in MyoD expression were observed (P=0.093), and when compared to SS, MyoD expression in the SOL was 37% lower in SD. No trends in the nutrition and exercise interventions modulating MyoD expression were observed (−51%, −36%, and −64% vs. SS in RD, CrSD, CrRD, respectively). Similarly, no between group differences in EDL MyoD expression were observed (P=0.57) with SD, RD, CrSD, and CrRD expressing 46%, 42%, 21%, and 27% lower MyoD, respectively, than SS. Combined Cr and RT preserved grip strength following DOX treatment, but MyoD expression does not seem to be involved in this myoprotection. It is possible that myogenic regulatory factors other than MyoD may be involved in Cr and RT‐induced protection against DOX myotoxicity.
cell biology,biochemistry & molecular biology,biology